Thoratec Corporation  

(Public, NASDAQ:THOR)   Watch this stock  
Find more results for David Todd Harris�
31.09
-0.17 (-0.54%)
After Hours: 31.10 0.00 (0.00%)
Nov 26, 4:27PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.93 - 31.49
52 week 22.50 - 43.00
Open 31.30
Vol / Avg. 342,248.00/922,554.00
Mkt cap 1.72B
P/E 34.66
Div/yield     -
EPS 0.90
Shares 55.00M
Beta 0.74
Inst. own 97%
Feb 2, 2015
Q4 2014 Thoratec Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 20, 2014
Thoratec Corp at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 12, 2014
Thoratec Corp at Credit Suisse Healthcare Conference
Nov 5, 2014
Q3 2014 Thoratec Corp Earnings Call - Webcast
Nov 5, 2014
Q3 2014 Thoratec Corp Earnings Release
Sep 10, 2014
Thoratec Corp at Morgan Stanley Healthcare Conference
Sep 4, 2014
Thoratec Corp at Barrington Research Fall Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 2.74% 14.58%
Operating margin 1.99% 19.40%
EBITD margin - 22.98%
Return on average assets 1.46% 9.84%
Return on average equity 1.75% 11.61%
Employees 951 -
CDP Score - -

Address

6035 Stoneridge Drive
Pleasanton, CA 94588
United States - Map
+1-925-8478600 (Phone)
+1-925-8478574 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (HF) patients. The Company develops, manufactures and markets medical devices used for circulatory support. For advanced HF, its primary product lines are its ventricular assist devices (VADs), which include the Thoratec Paracorporeal Ventricular Assist Device (PVAD), the Thoratec Implantable Ventricular Assist Device (IVAD), the HeartMate Left Ventricular Assist System (HeartMate XVE), and the HeartMate II Left Ventricular Assist System (HeartMate II). For acute HF, its product lines are the CentriMag Acute Circulatory System (CentriMag) and for pediatric patients the PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS). In July 2014, Thoratec Corp acquired Apica Cardiovascular Limited.

Officers and directors

Neil F. Dimick CPA Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Taylor C. Harris Chief Financial Officer, Vice President
Age: 38
Bio & Compensation  - Reuters
Niamh Louise Pellegrini President - North America
Age: 48
Bio & Compensation  - Reuters
David A. Lehman Senior Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Vasant Padmanabhan Ph.D. Senior Vice President - Technical Operations
Age: 47
Bio & Compensation  - Reuters
D. Keith Grossman President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
J. Daniel Cole Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven H. Collis Independent Director
Age: 52
Bio & Compensation  - Reuters
William A. Hawkins III Independent Director
Age: 60
Bio & Compensation  - Reuters
Paul A. LaViolette Independent Director
Age: 56
Bio & Compensation  - Reuters